-
Shandong cracks down on fraud and insurance fraud to recover more than 1.5 billion medical insurance funds in 2021
Time of Update: 2022-05-11
. Guo Jishui said that in terms of raising and using long-term care funds, Shandong is a province with a large elderly population, and there is a greater demand for basic living care and closely related medical care services for long-term disabled people .
-
China Resources Double Crane and Shenzhen Hanyu Pharmaceutical reached a strategic partnership
Time of Update: 2022-05-11
Recently, China Resources Double Crane signed a strategic cooperation agreement with Shenzhen Hanyu Pharmaceutical Co.
In the designated area, the product regards China Resources Shuanghe as the first partner to make an agreement in principle, and the specific product cooperation agreement is signed separately .
-
AZ enters Chinese medicine, siRNA leader targets the Chinese market, and the first biosimilar drug of aflibercept is applied for listing
Time of Update: 2022-05-11
Novartis' revenue in China in the first quarter of 800 million US dollars, the growth rate is higher than that of Europe and the United States On April 26, Novartis announced its financial report for the first quarter of 2022.
-
In vitro diagnostic company dividends are generous!
Time of Update: 2022-05-11
[Pharmaceutical Network Industry News] On the evening of April 14, while disclosing the 2021 annual report, the in vitro diagnostic company Shuo Shi Bio also announced the annual dividend plan, which plans to distribute 100 yuan for every 10 shares .
-
The Municipal Sludge Treatment and Disposal Seminar dances with the Hazardous Waste Management Forum!
Time of Update: 2022-05-11
[Pharmaceutical Network Conference Forum] Today, the municipal sludge treatment and disposal seminar and the collaborative pollution reduction and carbon reduction, hazardous waste environmental pollution control and resource utilization forum both appeared .
-
Good news for 300 million cardiovascular and cerebrovascular patients!
Time of Update: 2022-05-10
In addition to the price reduction of imported drugs, 2 domestic enterprises of irbesartan and hydrochlorothiazide tablets have also been selected, namely: Nanjing Zhengda Tianqing's 14-piece product, the winning price per box is 14.
-
Stricter supervision, a group of pharmaceutical giants were "named" for violations
Time of Update: 2022-05-10
In response, Eli Lilly also responded that the company is making necessary changes to the representation of financial indicators that do not conform to generally accepted accounting principles in accordance with the guidance of the US SEC .
-
7 varieties of selected medicines will be purchased with volume, which will be implemented from May 20th
Time of Update: 2022-05-10
[Pharmaceutical Network Industry News] Recently, the Office of the Joint Conference on Centralized Purchasing of Medicines and Medical Consumables in Jiangxi Province issued the "Notice on the Implementation of the Results of the Selection of the Procurement of Medicines in the Four Provinces Alliance of Gansu, Guangdong, Henan and Hubei" (hereinafter referred to as the "Notice") .
-
It is not easy to innovate and transform, and 4 senior executives of "First Brother Medicine" have resigned within 1 year
Time of Update: 2022-05-10
[Pharmaceutical Network Industry News] Recently, Hengrui Pharmaceutical, the "first brother of medicine", announced that Zou Jianjun, the company's deputy general manager, applied for his resignation as the company's deputy general manager due to personal reasons .
-
The price of 26 drugs has been reduced, and the human growth hormone of Kinsey Pharmaceuticals has dropped by nearly 30%
Time of Update: 2022-05-10
[Pharmaceutical Network Industry News] Recently, the Henan Provincial Pharmaceutical Purchasing Platform issued the "Notice on the Publicity of 26 Drugs with Price Reductions such as Tobramycin Eye Drops" .
According to the notice, the Belgian Alcon Tobramycin Eye Drops (5ml:15mg) originally had a price limit of 13.
-
TNF-α antibody drug market competition is becoming more and more intense, and product price reduction has become a trend
Time of Update: 2022-05-10
In the domestic market, in recent years, with the continuous entry of infliximab and adalimumab biosimilar companies, the TNF-α antibody drug market has become more competitive, and product price reductions have become a trend .
-
A group of medical companies released a quarterly report, and the revenue generally showed an increasing trend
Time of Update: 2022-05-10
The first quarterly report of 2022 shows that in the first quarter of this year, Mindray Medical’s investment in research and development reached 742 million yuan, accounting for 10.
-
The research and development of class 1 new drugs of traditional Chinese medicine is accelerated!
Time of Update: 2022-05-10
Judging from the new class 1 traditional Chinese medicine drugs under development, the indications include antidepressant drugs, in addition to Taizishenyue Capsules, also include Chaijin Jieyu Anshen Tablets, which have been approved for clinical use and are indicated for depression (liver depression and spleen deficiency type) .
-
100 million yuan of antibacterial drug varieties, the first home to comment on this one!
Time of Update: 2022-05-10
According to public information, Bihuan Pharmaceutical is mainly engaged in the research and development, production and sales of chemical drugs.
-
The number of innovative drugs in China is growing at a blowout, and the innovation of many pharmaceutical companies is accelerating
Time of Update: 2022-05-10
With continuous R&D investment, many local pharmaceutical companies have significantly accelerated their innovation, and their innovation achievements have also yielded fruitful results .
-
The drug has changed hands five times, and multinational pharmaceutical giant GSK has spent $1.9 billion to "take over"
Time of Update: 2022-05-10
9 billion to acquire Sierra Oncology, a company that develops targeted therapy drugs for rare tumors, and at the same time it will acquire the core drug Momelotinib owned by the latter .
-
Pharmaceutical companies promote digital development, which has become the general trend in the industry
Time of Update: 2022-05-10
[Pharmaceutical Network Industry News] In recent years, the state has begun to further meet the people's needs for convenient medical services by vigorously supporting the innovation of the "Internet +" medical service model .
-
It is difficult to develop new drugs, and a large number of drugs end in clinical failure
Time of Update: 2022-05-10
Some industry insiders who have been engaged in new drug research and development for many years said that there are five main reasons for the failure of the management of new drug research and development projects they participated in, including project approval mistakes, lack of project-matching stakeholders, uncertainty in technical risks, and late R&D application progress.
-
The news of layoffs in the pharmaceutical industry continues, but CXO companies are aggressively "recruiting"
Time of Update: 2022-05-10
According to statistics, as of April 19, the 2021 annual reports disclosed by nearly 200 domestic listed pharmaceutical companies showed that the total number of employees of about 50 companies appeared.
-
Chinese herbal medicines in many places are accelerating their "going overseas", and the export value continues to grow
Time of Update: 2022-05-10
For example, according to the statistics of Bozhou Customs, in 2021, Bozhou will export 15,000 tons of Chinese medicinal materials and Chinese patent medicines, worth 510 million yuan, accounting for 69.
